Novartis' breast cancer treatment wins FDA approval

The U.S. Food and Drug Administration (FDA) said on Friday that it had approved Novartis AG's treatment in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

This study is a multi ‐institutional validation of that algorithmic model in 620 additional estrogen receptor positive breast cancer cases, with outcome data on 310 cases, named in this study as the Rochester Modified Magee algorithm (RoMMa). RoMMa correctly predicted 85% (140/164) and 100% (17/17) of cases to have a low‐ or high‐risk ODX recurrence score, respectively, consistent with the original publication. Applying our own risk stratification criteria, in patients who received appropriate hormonal therapy, only one of the 45 (2.0%) patients classified as low risk by our original algorithm have been ass...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Cancer Network spoke with Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, on how ribociclib plus hormone therapy extends survival for patients with premenopausal advanced HR-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
In this study we performed disease-progression modeling in postmenopausal patients with early breast cancer who had received 5 years of postoperative hormone therapy. Clinical data from postmenopausal patients who had received postoperative hormonal therapy and met the predefined selection criteria were retrospectively collected in an anonymized way. Disease-progression modeling and simulations were performed using NONMEM version 7.42. A first-order deterioration model with a combination of a symptomatic model (when a drug effect provides a transient bad effect by offsetting the severity of the disease) and a disease-modif...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Pharmacol Source Type: research
Clinical calculator could spare breast cancer patients 5 years of unnecessary hormone therapy.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
(MediaSource) A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Combining ribociclib with hormone therapy found to cut risk of death by up to a thirdYounger women with breast cancer have been given the hope of living longer after what is described as “one of the greatest advances in breast cancer research in recent decades”.Adding ribociclib, a targeted drug that disrupts cancer cells, to standard hormone therapy was found to boost survival among premenopausal patients who have an advanced form of the disease.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Breast cancer Medical research Drugs Health Society NHS Science UK news World news Source Type: news
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.The study involved 672 women aged 25 to 59 when the study began who had advanced hormone-receptor positive/HER2- breast cancer. Seventy percent of the women who took the combination therapy wer...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
SATURDAY, June 1, 2019 -- Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found. The drug, called Kisqali (ribociclib), is already approved for treating such patients...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
SATURDAY, June 1, 2019 -- Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found. The drug, called Kisqali (ribociclib), is already approved for treating such patients...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Conclusion: Women with persistent VMS are more likely to be diagnosed with breast cancer than women who never experienced VMS, but not more likely to die from breast cancer.
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Hormonal Therapy | Hormones | Women